-
Retatrutide APIRetatrutide API (CAS 2381089-83-2), a first-in-class peptide GLP-1/GIP/GCG triple receptor agonist developed by Eli Lilly, is a breakthrough API for the treatment of type 2 diabetes and obesity.read more
-
Terlipressin FDATerlipressin API (Terlipressin Active Pharmaceutical Ingredient) is a synthetic long-acting vasopressin analog with the chemical identifier CAS 14636-12-5. It is a core raw material for critical careread more
-
Semaglutide Raw MaterialSemaglutide is a new-generation long-acting GLP-1 receptor agonist API. With the CAS number 910463-68-2, it appears as a white to off-white crystalline powder. CAS Number 910463-68-2read more
-
Liraglutide APILiraglutide API is a high-end active pharmaceutical ingredient (API) of the GLP-1 receptor agonist class. It is the core raw material for blood glucose control in type 2 diabetes and chronic weightread more
-
Carbetocin APICarbetocin (CAS 37025-55-1) is a long-acting synthetic oxytocin analog and a classic pharmaceutical raw material in polypeptide synthesis. With years of clinical validation and process optimization,read more
-
Tamoxifen Citrate PowderTamoxifen Citrate Powder (CAS 54965-24-1) is one of the most widely used and longest-established anti-estrogen antitumor raw materials in global clinical practice, especially effective on theread more
-
Epalrestat FDAEpalrestat CAS 82159-09-9 is the only globally marketed aldose reductase inhibitor API, first-line treatment for diabetic peripheral neuropathy. It blocks the polyol pathway, reduces sorbitolread more
-
Finerenone APIFinerenone API (CAS 1050477-31-0) is a new-generation nonsteroidal cardiorenal protective drug substance with highly selective mineralocorticoid receptor antagonism, providing core pharmaceutical rawread more
-
Estradiol APIOur estradiol API series consists of key steroidal estrogen raw materials, including natural endogenous estradiol API (CAS 50-28-2), synthetic potent Estradiol valerate (CAS 979-32-8), andread more
-
Dydrogesterone APIDydrogesterone API (CAS 152-62-5) is a highly selective progestogen API, mainly used for the treatment of female endocrine and reproductive system disorders. It specifically binds to progesteroneread more
-
Orforglipron APIOrforglipron API (CAS 2212020-52-3) is a pioneering oral non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly. As a breakthrough Orforglipron raw material (API) for type 2read more
Retatrutide is supplied as a lyophilized powder and must be reconstituted before use in research studies. It is crucial to follow the correct procedure to ensure the peptide remains stable and...
Dec 8, 2024 · Between May 13, 2021, and June 13, 2022, 281 participants (mean age 56·2 years [SD 9·7], mean duration of diabetes 8·1 years [7·0], 156 [56%] female, and 235 [84%] White) were randomly...
Retatrutide is a novel peptide under investigation for its potential in promoting weight loss, enhancing fat metabolism, and regulating blood glucose levels. Retatrutide is a triple receptor...
The bulk of retatrutide’s benefit is a result of its ability to decrease energy intake via delayed gastric emptying and increased control of hunger signals in the central nervous system. Dosage:...
Retatrutide, also known as LY3437943, is a glucagon-like peptide 1 agonist; what separates this peptide from the others is it also targets gastric inhibitory polypeptide receptor (GIPR) and glucagon...
May 16, 2024 · Retatrutide (also known as tirzepatide) is a novel medication aimed at treating obesity and potentially type 2 diabetes. It works through a unique triple mechanism by targeting the...
